Should You Start Levothyroxine for TSH 5 with Fatigue?
No, do not start levothyroxine for a TSH of 5 mIU/L, even with fatigue present. The evidence clearly shows that treatment at this level does not improve symptoms, and fatigue in this context is unlikely to respond to thyroid hormone replacement 1, 2.
Why Treatment is Not Indicated
TSH Threshold for Treatment
The established guidelines and recent evidence converge on a clear threshold:
- TSH <7-10 mIU/L: Treatment is not recommended 3, 2
- Levothyroxine therapy is only reasonable when TSH is persistently >10 mIU/L 3
- For TSH between 7-10 mIU/L, treatment may be considered in select cases with cardiovascular risk factors 4
Your patient's TSH of 5 mIU/L falls well below any treatment threshold.
The Fatigue Will Not Improve
Multiple randomized controlled trials demonstrate that:
- Levothyroxine does not improve hypothyroid symptoms or fatigue when TSH <10 mIU/L 1, 2
- In a 2025 pilot RCT, there was no difference in ThyPRO-Hypothyroid Symptoms or Tiredness scores between levothyroxine and placebo groups 1
- Symptoms related to vitality and quality of life in subclinical hypothyroidism often persist despite levothyroxine treatment 5
The fatigue has another cause—pursue alternative explanations rather than attributing it to mild TSH elevation.
Critical Next Steps
Confirm the Diagnosis First
Before any treatment consideration:
- Repeat TSH in 2-3 months to confirm persistence 2
- 62% of elevated TSH levels revert to normal spontaneously 2
- Check free T4 to ensure it's truly subclinical hypothyroidism (normal free T4)
- Consider checking TPO antibodies to assess autoimmune risk and progression likelihood
Investigate the Actual Cause of Fatigue
Look for:
- Anemia (CBC with iron studies)
- Vitamin D and B12 deficiency
- Sleep disorders (sleep apnea screening)
- Depression and anxiety
- Diabetes and metabolic syndrome
- Medication side effects
- Chronic kidney disease
Important Caveats and Pitfalls
Avoid Overtreatment Risks
The FDA label explicitly warns that levothyroxine has a narrow therapeutic index 6. Overtreatment causes:
- Cardiovascular complications: atrial fibrillation, increased heart rate, angina, arrhythmias 6
- Bone loss: decreased bone mineral density, particularly in postmenopausal women 6
- Neuropsychiatric symptoms: anxiety, insomnia, irritability 6
These risks are not justified when treating TSH of 5 mIU/L, where no benefit exists.
The Prescription Epidemic
Thyroid hormone prescriptions have increased 30% in the last decade in the U.S., largely driven by inappropriate treatment of mild subclinical hypothyroidism 2. A 2025 European survey found 7.5% of endocrinologists would consider thyroid hormones for euthyroid patients with unexplained fatigue—a practice that lacks evidence and contributes to overuse 7.
Special Populations to Consider
If Your Patient is Pregnant or Planning Pregnancy
This changes everything:
- Pregnant women with elevated TSH should be treated to restore TSH to reference range 3
- This is based on associations between high TSH and fetal wastage or neuropsychological complications 3
If Your Patient is Elderly
- Age-related TSH increases are physiologic 4
- The upper limit of normal TSH is 7.5 mIU/L for patients >80 years 2
- Treatment may be harmful in elderly patients with subclinical hypothyroidism 2
If Your Patient Has Cardiovascular Risk Factors
- Patients under age 65 with cardiovascular risk factors may benefit from treatment when TSH is 7-10 mIU/L 4, 5
- At TSH of 5, this still does not apply
The Bottom Line Algorithm
For TSH 5 mIU/L with fatigue:
- Do not start levothyroxine
- Repeat TSH and free T4 in 2-3 months
- Pursue alternative causes of fatigue aggressively
- If TSH remains 5-7 mIU/L on repeat: monitor annually, no treatment
- If TSH rises to 7-10 mIU/L: consider treatment only if age <65 with cardiovascular risk factors
- If TSH rises to >10 mIU/L: initiate levothyroxine 3, 8
The evidence is clear: treating subclinical hypothyroidism with TSH <7-10 mIU/L does not improve symptoms and exposes patients to unnecessary risks 1, 2.